Scalper1 News
Big biotech Biogen Idec (BIIB) led a passel of medical firms in reporting Q3 earnings early Wednesday, but Biogen stock was down nearly 8% in early trading on the stock market today as sales of its lead drug disappointed investors. Earlier, Biogen stock touched a five-month low of 290. Biogen’s Q3 earnings rose 61% over the year-earlier quarter to $3.80 a share, beating analysts’ estimates by 34 cents. Sales rose 37% to $2.5 billion, in line with Scalper1 News
Scalper1 News